Enhanced interleukin-1β in hypercholesterolemia: Effects of simvastatin and low-dose aspirin

Circulation

Volumn 108, Issue 14, 2003, Pages 1673-1675

  Ferroni, Patrizia ^a   Martini, Francesca ^a   Cardarello, Cristiano M ^a   Gazzaniga, Pier Paolo ^a   Davì, Giovanni ^a,b   Basili, Stefania ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b Center of Excellence on Aging   (Italy)

Author keywords

Aspirin; Hypercholesterolemia; Inflammation; Platelets; Statins

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; INTERLEUKIN 1BETA; PADGEM PROTEIN; SIMVASTATIN; VON WILLEBRAND FACTOR; ANTITHROMBOCYTIC AGENT; INTERLEUKIN 1;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DRUG EFFECT; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; INFLAMMATION; MALE; MULTIPLE REGRESSION; PRIORITY JOURNAL; PROTEIN DETERMINATION; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE ACTIVATION; BLOOD; COMPARATIVE STUDY; MIDDLE AGED;

ADULT; AGED; ASPIRIN; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; INTERLEUKIN-1; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; SIMVASTATIN;

EID: 0141988868     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000094732.02060.27     Document Type: Article

References (15)

1. Ridker PM, Rifai N, Lowenthal SP. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation. 2001;103:1191-1193.
2. Cipollone F, Mezzetti A, Porreca E, et al. Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: effects of statin therapy. Circulation. 2002;106:399-402.
3. Ferroni P, Basili S, Vieri M, et al. Soluble P-selectin and proinflammatory cytokines in patients with polygenic type IIa hypercholesterolemia. Haemostasis. 1999;29:277-285.
4. Davi G, Averna M, Catalano I, et al. Increased thromboxane biosynthesis in type IIa hypercholesterolemia. Circulation. 1992;85:1792-1798.
5. Davi G, Romano M, Mezzetti A, et al. Increased levels of soluble P-selectin in hypercholesterolemic patients. Circulation. 1998;97:953-957.
6. Brandt E, Ludwig A, Petersen F, et al. Platelet-derived CXC chemokines: old players in new games. Immunol Rev. 2000;177:204-216.
7. von Hundelshausen P, Weber KS, Huo Y, et al. RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium. Circulation. 2001;103:1772-1777.
8. Lindemann S, Tolley ND, Dixon DA, et al. Activated platelets mediate inflammatory signaling by regulated interleukin 1β synthesis. J Cell Biol. 2001;154:485-490.
9. Notarbartolo A, Davi G, Averna M, et al. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. Arterioscler Thromb Vasc Biol. 1995;15:247-251.
10. Jialal I, Stein D, Balis D, et al. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation. 2001;103:1933-1935.
11. Burger PC, Wagner DD. Platelet P-selectin facilitates atherosclerotic lesion development. Blood. 2003;101:2661-2666.
12. Chong BH Murray B, Berndt MC, et al, Plasma P-selectin is increased in thrombotic consumptive platelet disorders. Blood. 1994;83:1535-1541.
13. McEver RP. Properties of GMP-140, an inducible granule membrane protein of platelets and endothelium. Blood Cells. 1990;16:73-83.
14. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med. 1994;330:1287-1294.
15. Weyrich AS, Elstad MR, McEver RP, et al. Activated platelets signal chemokine synthesis by human monocytes. J Clin Invest. 1996;97:1525-1534.